Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Amicus Therapeutics, Inc. (FOLD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
7.76+0.34 (+4.58%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close7.42
Open7.51
Bid7.76 x 3000
Ask8.28 x 1300
Day's Range7.41 - 7.78
52 Week Range5.91 - 12.63
Volume2,205,442
Avg. Volume3,777,575
Market Cap2.162B
Beta (5Y Monthly)1.32
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Amicus Therapeutics Receives Notification of PDUFA Date Extensions for AT-GAA

    PHILADELPHIA, May 10, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by 90 days for the Biologics License Application (BLA) for cipaglucosidase alfa and the New Drug Application (NDA) for miglustat, the two components of AT-GAA. The revised PDUFA action dates for miglustat and cipaglucosidase alfa are August 29, 2022 and October 29, 2022, respectively. The Company continues to expect the

  • GlobeNewswire

    CORRECTING AND REPLACING -- Amicus Therapeutics Announces First Quarter 2022 Financial Results

    1Q22 Galafold® Revenue Growth of 18.5% to $78.7M New Composition of Matter Patent for Galafold® Strengthens U.S. Patent Protection into 2038 Advancing U.S. and EU Regulatory Reviews and Launch Preparations for AT-GAA in Pompe Disease Positive Long-Term Data from Phase 1/2 Study of AT-GAA in Pompe Disease Presented at 2022 MDA Conference Conference Call and Webcast Today at 8:30 a.m. ET PHILADELPHIA, May 09, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Ami

  • GlobeNewswire

    Amicus Therapeutics Announces First Quarter 2022 Financial Results

    1Q22 Galafold® Revenue Growth of 18.5% to $78.7M New Composition of Matter Patent for Galafold® Strengthens U.S. Patent Protection into 2038 Advancing U.S. and EU Regulatory Reviews and Launch Preparations for AT-GAA in Pompe Disease Positive Long-Term Data from Phase 1/2 Study of AT-GAA in Pompe Disease Presented at 2022 MDA Conference Conference Call and Webcast Today at 8:30 a.m. ET PHILADELPHIA, May 09, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global b

Advertisement
Advertisement